Vera Therapeutics Quarterly Income Statement
NASDAQ: VERAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
29.88+0.15 (+0.50%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vera Therapeutics revenue and earnings
Vera Therapeutics reported a net loss of $109.5 million, compared with a loss of $76.5 million a year earlier. Diluted earnings per share came in at -$1.52.
Summary generated from market data by MetaCap's automated system. Methodology
Vera Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 112.49M | 125.13M | 94.21M | 83.93M | 80.14M | 57.19M | 48.91M | 49.80M | 37.34M | 31.11M | 27.03M | 21.76M |
| Research & Development | 60.08M | 86.01M | 59.31M | 56.47M | 58.20M | 41.28M | 33.35M | 40.31M | 29.31M | 23.20M | 20.79M | 16.10M |
| Operating Income | -112.49M | -125.13M | -94.21M | -83.93M | -80.14M | -57.19M | -48.91M | -49.80M | -37.34M | -31.11M | -27.03M | -21.76M |
| Interest Expense | 1.85M | 1.82M | 1.90M | 1.96M | 1.87M | 1.79M | 1.87M | 1.94M | 1.91M | 1.91M | 1.06M | 943.00K |
| Other Income (Expense) | 3.02M | 4.10M | 3.11M | 3.64M | 3.61M | 5.50M | 5.49M | 3.17M | 3.63M | 2.73M | 1.37M | 1.65M |
| Net Income | -109.47M | -121.03M | -91.10M | -80.29M | -76.53M | -51.69M | -43.42M | -46.63M | -33.71M | -28.38M | -25.66M | -20.10M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.52 | -1.69 | -1.39 | -1.26 | -1.20 | -0.81 | -0.72 | -0.85 | -0.62 | -0.56 | -0.54 | -0.45 |
| EPS (Diluted) | -1.52 | -1.69 | -1.39 | -1.26 | -1.20 | -0.81 | -0.72 | -0.85 | -0.62 | -0.56 | -0.54 | -0.45 |
| Shares Outstanding (Basic) | 71.84M | 71.48M | — | 63.85M | 63.79M | 63.67M | — | 54.90M | 54.73M | 50.97M | — | 44.36M |
| Shares Outstanding (Diluted) | 71.84M | 71.48M | — | 63.85M | 63.79M | 63.67M | — | 54.90M | 54.73M | 50.97M | — | 44.36M |
| EBITDA | -112.36M | -124.99M | -94.07M | -83.80M | -80.02M | -57.11M | -48.86M | -49.78M | -37.33M | -31.10M | -27.02M | -21.75M |
This table shows 12 quarterly periods of Vera Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow VERA's reporting calendar. What is a income statement?